Parkinson's disease (PD) is a complex syndrome for which there is no disease-modifying
treatment on the market. However, a group of drugs from the Glucagon-like peptide-1 (GLP …

The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's
disease (PD) reflects an incomplete knowledge of the underlying disease processes …

Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Highlights•GLP-1 analogs can cross the blood–brain barrier and stimulate the GLP-1
receptor in the brain.•Stimulation of the GLP-1 receptor has shown effects on mitochondrial …

Parkinson's Disease (PD) is a heterogeneous, long-term neurodegenerative condition, for
which there are no therapies proven to slow or stop progression. At the same time …

Aging is a crucial risk factor for common neurodegenerative diseases, such as Alzheimer's
disease (AD) and Parkinson's disease (PD). Limited options are available for the treatment …

Type 2 diabetes has been identified as a risk factor for Alzheimer's disease (AD) and
Parkinson's disease (PD). In the brains of patients with AD and PD, insulin signaling is …

Conclusion The GLP-1 analogs have neuroprotective properties. Considering that type 2
diabetes is a risk factor for cognitive impairment and dementia, the benefits of GLP-1 …

In the past few years, the development of pharmaceutical agents that enhance the
physiological effects of glucagon-like peptide-1 (GLP-1), either through GLP-1 receptor …

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent
data highlight similarities between neurodegenerative diseases, including PD and type 2 …